{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:24:02Z","timestamp":1783099442609,"version":"3.54.6"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Orthop Trauma Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hip fractures are a major complication of osteoporosis and are associated with high morbidity, mortality, and costs. Despite clear guideline recommendations, pharmacological osteoporosis treatment remains underutilized. In addition, medications that increase fall and fracture risk further contribute to fracture occurrence. The aim of this study was to assess guideline concordance of osteoporosis therapy and to quantify the prevalence of medications associated with increased fall and fracture risk prior to the fracture in patients admitted with femoral fractures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In this prospective observational study, 145 patients aged\u2009\u2265\u200955 years admitted with femoral neck, per- and subtrochanteric, femoral shaft and distal femur fractures to a tertiary academic trauma center between April and June 2025 were included. Pre-admission medication was assessed using structured medication reconciliation. Guideline concordance of pre-fracture osteoporosis therapy was evaluated according to the current Austrian osteoporosis guideline (Dimai et al., 2024). Fall-risk-increasing drugs (FRIDs) were identified using the STOPPFall criteria, and fracture-associated medications were recorded based on Austrian osteoporosis guideline-defined drug classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 145 included patients (mean age 80.4 years; 71% female), 117 (81%) met criteria for pharmacological osteoporosis treatment prior to the fracture, defined by a preexisting osteoporosis diagnosis or a 10-year fracture risk above the treatment intervention threshold using the FRAX\n                      <jats:sup>\u00ae<\/jats:sup>\n                      calculator. Only 9 (7.7%) of these patients were treated in accordance with guideline recommendations. A treatment gap was observed in 78.6% of therapy-eligible patients. At least one FRID was prescribed in 70% of patients, and 57% received at least one medication associated with increased fracture risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients presenting with femoral fractures demonstrate a substantial gap in guideline-concordant osteoporosis therapy and a high prevalence of medications associated with increased fall and fracture risk. These findings highlight important opportunities for systematic primary and secondary fracture prevention and structured medication review.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00402-026-06401-5","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:15:04Z","timestamp":1783052104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osteoporosis treatment gap prior to femoral fracture and prevalence of pharmacological risk factors: a prospective observational study"],"prefix":"10.1007","volume":"146","author":[{"given":"Lukas","family":"B\u00f6ck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kerschan-Schindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Frossard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hajdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Crevenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Anditsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunar","family":"Stemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"1\u20132","key":"6401_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M, Compston J, Cooper C, Stenmark J et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 8(1\u20132):136. https:\/\/doi.org\/10.1007\/s11657-013-0136-1","journal-title":"Arch Osteoporos"},{"issue":"Suppl 16","key":"6401_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00508-024-02441-2","volume":"136","author":"HP Dimai","year":"2024","unstructured":"Dimai HP, Muschitz C, Amrein K, Bauer R, Cejka D, Gasser RW et al (2024) Osteoporose\u2014Definition, Risikoerfassung, Diagnose, Pr\u00e4vention und Therapie (update 2024). Wien Klin Wochenschr 136(Suppl 16):599\u2013668. https:\/\/doi.org\/10.1007\/s00508-024-02441-2","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"6401_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M et al (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16(1):82. https:\/\/doi.org\/10.1007\/s11657-020-00871-9","journal-title":"Arch Osteoporos"},{"issue":"9","key":"6401_CR4","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00198-012-1964-3","volume":"23","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Od\u00e9n A, McCloskey EV, Johansson H, Wahl DA, Cooper C (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23(9):2239\u20132256. https:\/\/doi.org\/10.1007\/s00198-012-1964-3","journal-title":"Osteoporos Int"},{"issue":"6","key":"6401_CR5","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s00223-019-00611-3","volume":"105","author":"M Behanova","year":"2019","unstructured":"Behanova M, Reichardt B, Stamm TA, Zwerina J, Klaushofer K, Kocijan R (2019) Treatment effects of bisphosphonates and denosumab on survival and refracture from real-world data of hip-fractured patients. Calcif Tissue Int 105(6):630\u2013641. https:\/\/doi.org\/10.1007\/s00223-019-00611-3","journal-title":"Calcif Tissue Int"},{"key":"6401_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.6003","author":"SN Morin","year":"2025","unstructured":"Morin SN, Leslie WD, Schousboe JT (2025) Osteoporosis. JAMA. https:\/\/doi.org\/10.1001\/jama.2025.6003","journal-title":"JAMA"},{"issue":"5","key":"6401_CR7","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 104(5):1595\u20131622. https:\/\/doi.org\/10.1210\/jc.2019-00221","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"6401_CR8","doi-asserted-by":"publisher","first-page":"afac205","DOI":"10.1093\/ageing\/afac205","volume":"51","author":"M Montero-Odasso","year":"2022","unstructured":"Montero-Odasso M, van der Velde N, Martin FC, Petrovic M, Tan MP, Ryg J et al (2022) World guidelines for falls prevention and management for older adults: a global initiative. Age Ageing 51(9):afac205. https:\/\/doi.org\/10.1093\/ageing\/afac205","journal-title":"Age Ageing"},{"issue":"4","key":"6401_CR9","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/ageing\/afaa249","volume":"50","author":"LJ Seppala","year":"2020","unstructured":"Seppala LJ, Petrovic M, Ryg J, Bahat G, Topinkova E, Szczerbi\u0144ska K et al (2020) STOPPFall (screening tool of older persons prescriptions in older adults with high fall risk): a Delphi study. Age Ageing 50(4):1189\u20131199. https:\/\/doi.org\/10.1093\/ageing\/afaa249","journal-title":"Age Ageing"},{"issue":"11","key":"6401_CR10","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00228-012-1273-y","volume":"68","author":"A Agust\u00ed","year":"2012","unstructured":"Agust\u00ed A, Pag\u00e8s E, Cuxart A, Ballar\u00edn E, Vidal X, Teixidor J et al (2012) Exposure to medicines among patients admitted for hip fracture and 1-year mortality: a longitudinal study. Eur J Clin Pharmacol 68(11):1525\u20131531. https:\/\/doi.org\/10.1007\/s00228-012-1273-y","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"6401_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-020-05557-z","volume":"32","author":"E McCloskey","year":"2020","unstructured":"McCloskey E, Rathi J, Heijmans S, Blagden M, Cortet B, Czerwinski E et al (2020) The osteoporosis treatment gap in European primary care: a multicountry cross-sectional study. Osteoporos Int 32(2):251\u2013259. https:\/\/doi.org\/10.1007\/s00198-020-05557-z","journal-title":"Osteoporos Int"},{"key":"6401_CR12","doi-asserted-by":"publisher","first-page":"115071","DOI":"10.1016\/j.bone.2019.115071","volume":"142","author":"O Malle","year":"2019","unstructured":"Malle O, Borgstr\u00f6m F, Fahrleitner-Pammer A, Svedbom A, Dimai SV, Dimai HP (2019) Mind the gap: osteoporosis treatment after fracture in Austria (ICUROS). Bone 142:115071. https:\/\/doi.org\/10.1016\/j.bone.2019.115071","journal-title":"Bone"},{"issue":"12","key":"6401_CR13","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00198-018-4759-3","volume":"29","author":"CT Yeam","year":"2018","unstructured":"Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB (2018) Factors affecting medication adherence among patients with osteoporosis: a systematic review. Osteoporos Int 29(12):2623\u20132637. https:\/\/doi.org\/10.1007\/s00198-018-4759-3","journal-title":"Osteoporos Int"},{"issue":"1","key":"6401_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/jcm12010014","volume":"12","author":"GRA Mangano","year":"2022","unstructured":"Mangano GRA, Avola M, Blatti C, Caldaci A, Sapienza M, Chiaramonte R et al (2022) Non-adherence to anti-osteoporosis medication: factors and strategies. J Clin Med 12(1):14. https:\/\/doi.org\/10.3390\/jcm12010014","journal-title":"J Clin Med"},{"issue":"10","key":"6401_CR15","doi-asserted-by":"publisher","first-page":"e2438393","DOI":"10.1001\/jamanetworkopen.2024.38393","volume":"7","author":"WK Silverstein","year":"2024","unstructured":"Silverstein WK, Wang S, Alavinejad M, Sarnocinska A, Stall NM, Malikov K et al (2024) Antiosteoporosis medication prescriptions after fragility fractures. JAMA Netw Open 7(10):e2438393. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.38393","journal-title":"JAMA Netw Open"},{"issue":"8","key":"6401_CR16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.eprac.2023.05.001","volume":"29","author":"P Choksi","year":"2023","unstructured":"Choksi P, Gay BL, Haymart MR, Papaleontiou M (2023) Physician-reported barriers to osteoporosis screening: a nationwide survey. Endocr Pract 29(8):606\u2013611. https:\/\/doi.org\/10.1016\/j.eprac.2023.05.001","journal-title":"Endocr Pract"},{"issue":"11","key":"6401_CR17","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/jbmr.4701","volume":"37","author":"KAP Ralston","year":"2020","unstructured":"Ralston KAP, Hauser B, Paskins Z, Ralston SH (2020) Effective communication and the osteoporosis care gap. J Bone Min Res 37(11):2049\u20132054. https:\/\/doi.org\/10.1002\/jbmr.4701","journal-title":"J Bone Min Res"},{"issue":"6","key":"6401_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1001\/jama.2024.21653","volume":"333","author":"LC Kahwati","year":"2025","unstructured":"Kahwati LC, Kistler CE, Booth G, Sathe N, Gordon RD, Okah E et al (2025) Screening for osteoporosis to prevent fractures. JAMA 333(6):509. https:\/\/doi.org\/10.1001\/jama.2024.21653","journal-title":"JAMA"},{"key":"6401_CR19","doi-asserted-by":"publisher","first-page":"115081","DOI":"10.1016\/j.bone.2019.115081","volume":"130","author":"EL Simpson","year":"2019","unstructured":"Simpson EL, James MMS, Hamilton J, Wong R, Gittoes N, Selby P et al (2019) Clinical effectiveness of osteoporosis drugs: a network meta-analysis. Bone 130:115081. https:\/\/doi.org\/10.1016\/j.bone.2019.115081","journal-title":"Bone"},{"issue":"10","key":"6401_CR20","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1001\/jamainternmed.2016.4814","volume":"176","author":"JC Munson","year":"2016","unstructured":"Munson JC, Bynum JPW, Bell JE, Cantu R, McDonough C, Wang Q et al (2016) Prescription drug use before and after fragility fracture. JAMA Intern Med 176(10):1531. https:\/\/doi.org\/10.1001\/jamainternmed.2016.4814","journal-title":"JAMA Intern Med"},{"issue":"11","key":"6401_CR21","doi-asserted-by":"publisher","first-page":"e1915348","DOI":"10.1001\/jamanetworkopen.2019.15348","volume":"2","author":"RT Emeny","year":"2019","unstructured":"Emeny RT, Chang CH, Skinner J, O\u2019Malley AJ, Smith J, Chakraborti G et al (2019) Concurrent fracture-associated drugs and hip fracture risk. JAMA Netw Open 2(11):e1915348. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.15348","journal-title":"JAMA Netw Open"},{"issue":"6","key":"6401_CR22","doi-asserted-by":"publisher","first-page":"afad079","DOI":"10.1093\/ageing\/afad079","volume":"52","author":"J Hauff","year":"2023","unstructured":"Hauff J, Rottenkolber M, Oehler P, Fischer S, Gensichen J, Drey M et al (2023) Fall-risk-increasing drugs and fracture risk: a case\u2013control study. Age Ageing 52(6):afad079. https:\/\/doi.org\/10.1093\/ageing\/afad079","journal-title":"Age Ageing"}],"container-title":["Archives of Orthopaedic and Trauma Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00402-026-06401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00402-026-06401-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00402-026-06401-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:02:54Z","timestamp":1783098174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00402-026-06401-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6401"],"URL":"https:\/\/doi.org\/10.1007\/s00402-026-06401-5","relation":{},"ISSN":["1434-3916"],"issn-type":[{"value":"1434-3916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"5 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"242"}}